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Summary
Background.  —  Biological  diagnostic  criteria  for  diagnosing  aldosterone-producing  adenoma
(APA) are  not  well-established.
Aim.  —  The  aim  of  the  study  was  to  establish  the  best  biological  predictors  of  APA.producing  adenoma;
Hypertension;
Hypokalaemia;
Methods.  —  A  prospective  register  was  implemented  in  17  secondary  or  tertiary  hypertension
centres. The  inclusion  criterion  was  one  of  the  following:  onset  of  hypertension  before  40
years of  age;  history  of  hypokalaemia;  drug-resistant  hypertension  (resistant  to  three  drugs);
or spironolactone  efﬁciency  on  BP.
Abréviations: APA, aldosterone-producing adenoma; ARR, aldosterone-to-renin ratio; AVS, adrenal venous sampling; BP, blood pressure;
CT, computed tomography; PA, primary aldosteronism; ROC, receiver operating characteristic.
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Aldosterone-to-renin
ratio
Results.  —  Among  the  338  collected  cases,  192  patients  had  two  aldosterone-to-renin  ratio
(ARR) determinations  (after  1  hour  supine  and  at  least  1  hour  upright)  on  the  same  occasion.
Twenty-ﬁve  patients  (8.2%)  had  biological  hyperaldosteronism  and  an  adrenal  adenoma  identi-
ﬁed by  computed  tomography.  APA  was  histologically  conﬁrmed  in  all  12  patients  who  underwent
surgery. Histologically  proven  APAs  were  used  as  the  ‘gold  standard’  in  receiver  operating  char-
acteristic  (ROC)  curve  analysis.  ARRs  were  computed  with  a  minimum  renin  value  set  at  5  ng/L
to avoid  misclassiﬁcation  of  so-called  ‘low-renin  hypertension’.  To  predict  an  APA,  the  ARR  area
under the  ROC  curve  was  0.93.  A  supine  ARR  cut-off  value  of  32  ng/ng  provided  the  highest  sum
of sensitivity  (92%)  plus  speciﬁcity  (92%).  On  the  basis  of  an  ARR  ≥  32  ng/ng  in  the  supine  and/or
upright position,  sensitivity  reached  100%.
Conclusion.  —  The  proposed  cut-off  value  of  32  ng/ng  for  ARR  (minimum  renin  value  set  at
5 ng/L)  in  one  of  two  determinations  had  100%  sensitivity  and  72%  speciﬁcity  with  20%  positive
and 100%  negative  predictive  values  for  diagnosing  APA.
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Les  critères  biologiques  pour  le  diagnostic  d’un  adénome  de  Conn  ne  sont  pas  bien
établi.
Objectif. —  L’objectif  de  cette  étude  est  d’établir  les  seuils  biologiques  d’aldostérone  et  de
rénine permettant  de  prédire  un  adénome  de  Conn.
Méthodes.  —  Un  registre  prospectif  a  été  mis  en  œuvre  dans  17  centres  de  l’hypertension.  Le
critère d’inclusion  dans  le  registre  était  l’un  des  éléments  suivants  :  apparition  de  l’hypertension
avant 40  ans,  antécédent  d’hypokaliémie,  hypertension  artérielle  résistante  ou  efﬁcacité  trop
importante  de  la  spironolactone  dans  le  traitement  de  l’hypertension.
Résultats.  —  Parmi  les  338  cas  recueillis,  192  patients  ont  eu  deux  déterminations  successives  de
rénine et  d’aldostérone  (une  heure  en  position  couchée  et  au  moins  une  heure  debout).  Vingt-
cinq patients  (8,2  %)  avaient  un  hyperaldostéronisme  biologique  et  un  adénome  surrénalien
identiﬁé par  une  tomodensitométrie.  Une  histologie  compatible  avec  un  adénome  de  Conn  a
été conﬁrmée  chez  les  les  12  patients  qui  ont  été  opérés.  Un  adénome  de  Conn  histologique-
ment conﬁrmé  a  été  utilisé  comme  « gold  standard  » pour  l’établissement  des  courbes  ROC.
Les rapports  aldostérone/rénine  (RAR)  ont  été  calculés  avec  une  valeur  minimale  de  rénine
ﬁxée à  5  ng/L.  Aﬁn  de  prédire  un  adénome  de  Conn,  l’aire  sous  la  courbe  ROC  du  RAR  était  de
0,93. Une  valeur  de  RAR  couchée  supérieure  à  32  ng/ng  avait  les  sensibilités  (92  %)  et  spéciﬁcité
(92 %)  les  plus  élevées.  Sur  la  base  d’un  RAR  supérieur  à  32  ng/ng  en  décubitus  dorsal  et/ou  en
orthostatisme,  la  sensibilité  atteint  100  %.
Conclusion.  — Le  seuil  de  RAR  à  32  ng/ng  (valeur  minimale  de  rénine  à  5  ng/L)  lors  de  l’une  des
deux déterminations,  soit  en  décubitus  dorsal,  soit  en  orthostatisme  a  une  sensibilité  de  100  %,
une spéciﬁcité  de  72  %,  une  valeur  prédictive  positive  de  20  %  et  une  valeur  prédictive  négative
de 100  %  pour  le  diagnostic  d’un  adénome  de  Conn.
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ackground
rimary  aldosteronism  (PA)  is  one  of  the  commonest  forms
f  secondary  hypertension  [1]  and  diagnosis  of  PA  has
eceived  much  attention  in  recent  years  [2—6]. Once  PA
s  conﬁrmed,  the  subtype  must  be  determined  in  order
o  guide  treatment.  Almost  one-third  of  PA  cases  are  due
o  aldosterone-producing  adenoma  (APA)  and  are  surgically
urable.  Two-thirds  of  PA  cases  are  related  to  idiopathic
drenal  primary  aldosteronism,  frequently  with  nodular
drenal  hyperplasia  [7].  APA  has  been  reported  to  carry
 higher  risk  of  left  ventricular  hypertrophy,  stroke  and
hronic  kidney  disease  [8—13]. A  surgical  alternative  to
ong-term  drug  therapy  would  reduce  costs  and  increase
atients’  quality  of  life.  PA  was  initially  deﬁned  as  hyper-
ension  associated  with  increased  aldosterone  and  low  renin
oncentrations.  High  concentrations  of  aldosterone  lead  to
K
i
ts  droits  réservés.
he sodium  retention  responsible  for  hypertension  and  renal
otassium  loss  causing  hypokalaemia.  However,  in  half  of
A  cases,  kalaemia  is  within  the  normal  range  and  some-
imes  even  blood  pressure  (BP)  is  normal.  Thus,  diagnosis
f  PA  is  not  easy  and  screening  for  possible  PA,  which  was
nitially  restricted  to  hypertension  with  hypokalaemia,  had
o  be  extended  to  cases  of  resistant  hypertension  [14,15].
he  diagnosis  of  PA  remains  biological,  associating  high  con-
entrations  of  aldosterone  with  low  concentrations  of  renin.
any  authors  have  used  the  aldosterone-to-renin  ratio  (ARR)
o  deﬁne  PA  and  several  cut-off  values  have  been  proposed
14,16—22].  Furthermore,  to  avoid  diagnosis  of  low-renin
ypertension,  minimum  values  for  renin  and/or  aldosterone
ave  been  advocated  for  calculating  the  ARR.  As  noted  by
aplan  [23], there  are  ‘considerable  differences  in  the  def-
nition  of  an  elevated  ARR’.  Two  strategies  have  been  used
o  deﬁne  the  ARR.  The  ﬁrst,  representing  the  upper  values
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obtained  in  unselected  essential  hypertensive  subjects,  led
to  a  lower  cut-off  value  and  a  consequently  higher  percent-
age  of  PA  (up  to  39%  of  hypertensives).  The  second  is  based
on  minimal  ARR  values  in  patients  with  an  APA.  A  more
suitable  strategy  used  by  Bernini  et  al.  [24]  to  assess  ARR
cut-off  values  is  based  on  receiver  operating  characteristic
(ROC)  analysis.  In  their  single  centre  study,  they  proposed
an  aldosterone-to-plasma  renin  activity  cut-off  value  and
reported  a  high  percentage  of  APA  (8.4%)  and  IHAP  (author  to
deﬁne  at  proof  stage)  (12.7%)  in  newly  diagnosed  hyperten-
sives.  In  the  PAPY  study,  Rossi  et  al.  [25]  reported  that  ARR
based  on  measurement  of  active  renin  is  a  valuable  alterna-
tive  to  that  based  on  plasma  renin  activity.  Using  a  similar
strategy,  we  conducted  a  prospective  multicentre  study  to
determine  an  ARR  threshold  for  detecting  an  APA.
Methods
A  prospective  register  was  implemented  in  17  secondary  or
tertiary  hypertensive  centres.  The  inclusion  criterion  was
one  of  the  following:  onset  of  hypertension  before  40  years
of  age;  history  of  hypokalaemia;  drug-resistant  hypertension
(resistant  to  three  drugs);  or  spironolactone  efﬁciency  on
BP.  The  register  opened  in  October  2006  and  closed  in  June
2007  when  300  consecutive  case  reports  were  recorded  as
speciﬁed  in  the  study  protocol.
For  each  patient,  the  following  data  were  col-
lected:  anthropomorphic  variables  and  lifestyle  (weight,
height,  smoking  habits,  alcohol  consumption,  liquorice  con-
sumption);  hypertension  history  (duration,  family  history,
efﬁciency  of  spironolactone  if  available  and  potassium
supplementation;  sitting  BP  [measured  three  times  at  2-
minute  intervals  after  a  5-minute  rest;  the  averages  of
the  three  BP  measurements  were  calculated;  validated
automatic  sphygmomanometers  were  used  in  all  cen-
tres]);  cardiovascular  complications  (myocardial  infarction,
arrhythmia  and  stroke);  biological  variables  (kalaemia,  cre-
atininaemia,  plasma  bicarbonate,  24-hour  urinary  excretion
of  creatinine,  sodium,  potassium,  albumin  and  aldosterone);
plasma  aldosterone  and  active  renin  (both  expressed  in
ng/L),  determined  after  1  hour  in  a  supine  position  and  after
at  least  1  hour  in  an  upright  position.
A minimum  plasma  renin  value  of  5  ng/L  was  set  to
calculate  the  ARR.  Treatments  that  might  interfere  with
the  renin-angiotensin  system  were  not  allowed;  however,
oral  contraceptive  and  hormonal  replacement  therapies
were  not  stopped  or  modiﬁed.  A  wash-out  period  prior
to  ARR  screening  was  2  weeks  for  angiotensin-converting
enzyme  inhibitors,  angiotensin  receptor  blockers,  beta-
blockers  and  diuretics  (except  for  spironolactone)  and  4
weeks  for  spironolactone;  however,  in  22  patients  with
ischaemic  myocardial  disease,  beta-blockers  could  not  be
interrupted.  When  necessary,  authorized  treatments  were
calcium  channel  blockers  (non-dihydropyridine  or  long-
acting  dihydropyridine),  central-acting  agents  (rilmenidine)
and  alpha-blockers  (slow-release  prasozin,  urapidil).  Sodium
diet  and  potassium  supplementation  (if  applicable)  were  not
modiﬁed.  Cases  reports  containing  unauthorized  drugs  were
discarded  (n  =  6).
Using  complete  case  report  forms,  a  blind  outcome  com-
mittee  (J.-P.F.  and  J.-P.B.)  established  the  diagnosis  of  PA.
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he  ARR  cut-off  value  of  23  ng/ng  was  used  to  suspect  a  PA,
ith  the  minimal  renin  concentration  set  at  5  ng/L.  This  cut-
ff  value  was  chosen  because  it  was  the  lowest  reported  in
he  literature  [17]. However,  in  ﬁve  case  reports,  the  ARR
as  greater  than  23  ng/ng  and  computed  tomography  (CT)
cans  were  not  available;  the  diagnosis  could  not  be  made
nd  these  cases  were  excluded  for  incomplete  data.  Actu-
lly,  in  the  remaining  patients,  the  minimum  ARR  value  used
y  the  investigators  for  high-resolution  angiographic  CT-scan
as  14.5  ng/ng.  Thus,  a  CT-scan  was  also  performed  in  99
atients  (70%)  in  whom  the  ARR  was  lower  than  23  ng/ng.
wenty-two  other  case  reports  were  also  excluded  due  to
ncomplete  data.
tatistical analysis
ata  were  expressed  as  mean  values  ±  standard  deviations.
ean  values  between  groups  were  compared  using  Student’s
 test.  Categorical  variables  were  compared  using  the  Chi2
est.  ROC  analysis  was  used  to  evaluate  the  diagnostic  power
f  different  ARR  levels.  To  estimate  classiﬁcation  accuracy
sing  ROC  analysis,  the  disease  status  of  each  patient  had
o  be  validated  without  error.  Thus,  we  chose  the  histo-
ogically  proven  cases  of  APA  as  the  gold  standards  for  the
OC  analysis.  ARR  is  a  continuous-scale  measurement.  Once
he  diagnosis  of  APA  for  each  patient  was  determined,  a
 ×  2  contingency  table  was  made.  Sensitivity  (i.e.  true  pos-
tive  rate)  and  speciﬁcity  (i.e.  true  negative  rate)  were
alculated  for  each  ARR  cut-off  value.  A  ROC  curve  that
lotted  sensitivity  against  (1—speciﬁcity)  was  drawn.  The
loser  the  area  under  the  ROC  curve  was  to  1,  the  more
ccurate  the  diagnostic  test.  The  Younden  score  (sensitiv-
ty  +  speciﬁcity—1)  provided  the  optimal  ARR  cut-off  value
o  diagnose  APA.  Data  analysis  used  Medcalc® 11.5.1.0  soft-
are.
esults
s  shown  on  the  ﬂow-chart  (Fig.  1),  among  the  338  col-
ected  cases,  305  met  all  the  inclusion  criteria,  192  patients
ad  two  ARR  determinations  (supine  and  upright)  and  25
atients  (8.2%)  had  biological  PA  and  an  adrenal  adenoma.
mong  them,  12  patients  chose  adrenalectomy  and  13
referred  pharmacological  treatments.  Five  patients  (two
mong  those  who  chose  adrenalectomy)  who  had  biologi-
al  PA  and  an  adrenal  adenoma  were  taking  a  beta-blocker.
mong  the  12  operated  patients,  only  six  had  adrenal  venous
ampling  (AVS);  in  each  case,  it  conﬁrmed  the  unilateral
ldosterone  secretion.  No  technical  failure  was  reported
y  the  investigators.  In  all  those  who  underwent  unilateral
drenalectomy,  an  APA  was  conﬁrmed  by  histology.  Patients
reated  by  spironolactone  achieved  either  normalization
n  =  9)  or  signiﬁcant  reduction  (n  =  4)  in  BP  (BP  decrease  >  20%
r  use  of  fewer  antihypertensive  drugs).
Thus,  for  our  purpose,  the  12  patients  with  histologically
roven  APAs  were  compared  with  the  167  remaining  patients
ho  did  not  have  APAs.  The  mean  characteristics  of  patients
ith  histologically  proven  APAs  and  those  without  APAs  are
hown  in  Table  1.  BP  was  slightly,  but  not  signiﬁcantly,
igher  in  APA  patients  undergoing  similar  therapy  at  presen-
ation.  Four  of  the  12  (33%)  APA  patients  had  normal  serum
626  M.  Ducher  et  al.
Collectedcase reports:338
Reliablecasereports:305
Unilateraladenoma:25
HistologicallyprovenAPA:12 Non-operatedA PA:13
Casereportswith1or2ARR
determinations:274
Uncompletedcasereports:27
Unauthorizeddrugs:6
Casereportswithonly1ARR
determination:82
ObservationswithoutanA PA:150
Unilateralhyperplasia:10
Bilateralhyperplasia:7
Renalpatients:13
Renalarterystenosis:10
Malignanthypertension:3
Dualpathology:3
Pheochromocytoma:1
Liquorice:1
Analyzedcase reportswith2ARR
determinations:192
Figure 1. Flow-chart. APA: aldosterone-producing adenoma; ARR: aldosterone-to-renin ratio.
Table  1  Mean  characteristics  of  patients  with  and  without  aldosterone-producing  adenoma.
APA  (n  =  12) Non-APA  (n  =  167) Pa
Age  (years)  45  ±  10.5  51  ±  13  0.14
Men/women  (n/n)  5/7  73/94  0.87
Duration  of  hypertension  (years)  7.2  ±  1.4  10.1  ±  9.1  0.30
Ofﬁce  SBP  (mmHg)  162  ±  21  159  ±  13  0.68
Ofﬁce  DBP  (mmHg)  97  ±  17  95  ±  13  0.56
Number  of  antihypertensive  drugs  2.3  ±  1.1  2.2  ±  6.5  0.76
BMI  (kg/m2)  27.7  ±  4.6  27.6  ±  5.2  0.46
Kalaemia  (mmol/L)  3.4  ±  0.35  3.8  ±  1.3  <  0.001
eGFR  (mL/minute)  102  ±  42  103  ±  26  0.87
Bicarbonate  (mmol/L)  27.7  ±  2.5  26.4  ±  3.9  0.18
Supine  active  renin  (ng/L)  2.9  ±  2.5  5.4  ±  3.9  <  0.01
Standing  active  renin  (ng/L)  4.7  ±  6.7  10.6  ±  7.8  <  0.001
Supine  aldosterone  (ng/L)  276  ±  115  88  ±  78  <  0.001
Standing  aldosterone  (ng/L)  483  ±  318  200  ±  156  <  0.001
Supine  ARR  (ng/ng) 52.5  ±  24.5  14.0  ±  10.4  <  0.001
Standing  ARR  (ng/ng) 76.3  ±  42.7 25.0  ±  19.5  <  0.001
Data are mean ± standard deviation unless otherwise indicated. APA: aldosterone-producing adenoma; ARR: aldosterone-to-renin ratio
(with a minimum renin value set at 5 ng/L); BMI: body mass index; DBP: diastolic blood pressure; eGFR: estimated glomerular ﬁltration
rate; SBP: systolic blood pressure.
a P is the alpha risk of Student’s t test to compare mean values and of the Chi2 test to compare percentages.
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Figure 2. Receiver operating characteristic curve for active renin, aldosterone and aldosterone-to-renin ratio in 12 proven or 25 sus-
upine
r
w
w
v
opected aldosterone-producing adenomas (APAs) determined in the s
characteristic curve; ARR: aldosterone-to-renin ratio.
potassium  concentrations  (≥  3.5  mmol/L).  Bicarbonate  and
estimated  renal  function  (Cockcroft  and  Gault  formula)  did
not  differ  between  groups.  Supine  and  standing  active  renin
concentrations  were  signiﬁcantly  lower  and  aldosterone
concentrations  were  signiﬁcantly  higher  in  APA  patients.
Consequently,  supine  and  standing  ARRs  were  signiﬁcantly
higher  in  APA  patients.  The  area  under  the  ROC  curve  that
plotted  sensitivity  versus  (1—speciﬁcity)  for  supine  active
c
c
F position for 179 patients. AUC: area under the receiver operating
enin  was  0.72  (Fig.  2),  while  that  for  supine  aldosterone
as  0.92  (Fig.  2).  The  highest  area  under  the  ROC  curve
as  obtained  with  an  ARR  calculated  with  the  minimal
alue  of  active  renin  set  at  5  ng/L  (data  not  shown  for
ther  renin  threshold).  The  highest  area  under  the  ROC
urves  provided  the  highest  Younden  index  and  thus  the  best
ompromise  between  sensitivity  and  speciﬁcity.  As  shown  in
ig.  2,  the  AUC  for  the  ROC  analysis  was  0.93  for  supine
628  M.  Ducher  et  al.
Table  2  Diagnostic  power  of  the  different  biological  tests  determined  in  supine  position.
Renin  Aldosterone  ARR
Cut-off  values  (ng/L) 4.0  167  32
AUC  0.72  (0.65—0.79)  0.92  (0.90—0.97)  0.93  (0.89—0.96)
Sensitivity  (%)  83  (52—98)  92  (61—100)  92  (63—100)
Speciﬁcity  (%)  54  (46—62)  87  (81—92)  92  (87—96)
PPV  (%) 11  (6—20)  33  (18—52)  46  (25—68)
PNV  (%) 97  (92—100)  99  (96—100)  99  (97—100)
ed. A
curve
A
c
g
s
1
p
3
1
n
v
a
w
c
s
o
h
a
D
P
a
b
c
h
b
c
r
i
s
A
o
p
t
c
A
f
s
p
A
O
m
w
t
f
c
h
a
m
m
v
s
e
i
A
a
n
p
p
c
a
a
w
c
t
c
l
s
a
a
a
A
t
c
i
c
ﬁ
c
T
r
t
t
o
a
b
tData are mean (95% conﬁdence interval) unless otherwise indicat
at 5 ng/L); AUC: area under the receiver operating characteristic 
RR.  The  highest  Younden  coefﬁcients  with  corresponding
ut-off  values  for  aldosterone,  active  renin  and  ARR  are
iven  in  Table  2.  The  corresponding  ARR  cut-off  value  in  the
upine  position  was  32  ng/ng.  According  to  this  cut-off  value,
1  APAs  were  diagnosed.  An  ARR  >  32  ng/ng  in  the  upright
osition  revealed  the  remaining  APA.  The  cut-off  value  of
2  ng/ng  for  ARR  in  at  least  one  of  two  determinations  had
00%  sensitivity,  72%  speciﬁcity  and  20%  positive  and  100%
egative  predictive  values  for  diagnosing  an  APA.  Absolute
alues  of  active  renin  and  aldosterone  did  not  provide  any
dditional  information.  When  applied  to  the  25  patients,  in
hom  the  CT-scan  revealed  an  adrenal  adenoma,  the  ARR
ut-off  value  of  32  ng/ng  provided  a  speciﬁcity  of  92%  and  a
ensitivity  of  72%  (Fig.  2).
According  to  the  CT-scan  and  the  determined  thresh-
ld  of  32  ng/ng,  there  were  ﬁve  cases  of  bilateral  primary
yperplasia,  four  cases  of  unilateral  primary  hyperplasia  (no
denoma)  and  34  cases  of  idiopathic  hyperaldosteronism.
iscussion
rimary  aldosteronism  is  deﬁned  as  inappropriately  high  and
utonomous  aldosterone  secretion,  which  is  not  suppressible
y  sodium  loading.  Among  PA,  diagnosing  an  APA  is  of  clini-
al  interest  as  it  is  a  curable  cause  of  hypertension  in  about
alf  of  the  patients  [26], adrenalectomy  has  become  simpler
y  coelioscopy  and  APAs  are  associated  with  high  cardiovas-
ular  morbidity  and  renal  impairment  [27]. The  ARR,  which
eﬂects  aldosterone  hypersecretion  in  relation  with  renin,
s  currently  considered  to  be  the  most  reliable  tool  for  PA
creening.  The  aim  of  our  study  was  to  propose  a  reliable
RR  threshold  that  is  usable  as  a  ﬁrst  step  in  the  diagnosis
f  an  APA.
The  ARR  ﬁrst  proposed  by  Dunn  and  Espiner  [16]  in  1976
roved  to  be  the  best  for  differentiating  PA  from  essen-
ial  hypertension.  There  is  marked  heterogeneity  in  the
onditions  of  ARR  determination  and  therefore  in  proposed
RR  cut-off  values  [17,18,22,23,28].  However,  although  per-
ormed  in  different  conditions  in  a  multicentre  study  (PAPY
tudy),  ARR  determinations  showed  satisfactory  within-
atient  reproducibility  [29]. The  population  in  which  the
RR  cut-off  value  is  determined  is  of  major  importance.
ur  study  population  is  in  accordance  with  current  recom-
endations  [30]. In  our  study,  the  percentage  of  patients
ith  an  APA  was  very  similar  to  that  reported  in  the  litera-
ure.  As  recommended  by  Plouin  et  al.  [20], minimum  values
or  renin  and/or  aldosterone  must  be  determined  to  avoid
c
(
w
[RR: aldosterone-to-renin ratio (with a minimum renin value set
; PPN: negative predictive value; PPV: positive predictive value.
lassifying  low-renin  hypertension  as  PA.  In  our  study,  the
ighest  area  under  the  ROC  curve  for  ARR  was  obtained  with
 minimal  value  of  active  renin  set  at  5  ng/L.  To  set  a  mini-
al  renin  concentration  at  5  ng/L  is  equivalent  to  setting  a
inimal  aldosterone  concentration  at  160  ng/L.
There  are  considerable  differences  in  deﬁnitions  of  ele-
ated  ARR,  with  most  ARR  cut-off  values  set  as  the  mean  +  2
tandard  deviations  of  values  obtained  in  patients  with
ssential  hypertension.  A  methodology  well  suited  to  deﬁn-
ng  an  ARR  cut-off  is  ROC  analysis.  In  our  study,  diagnosis  of
PA  was  based  on  the  association  of  biological  PA,  an  adrenal
denoma  on  CT-scan  and  a  histological  proven  adrenal  ade-
oma  in  operated  patients.  The  proportion  of  operated
atients  was  similar  to  that  usually  reported  [18]. In  the  12
atients  who  underwent  surgery,  histological  analysis  always
onﬁrmed  the  APA.  For  the  other  cases,  spironolactone  was
lways  efﬁcient  in  normalizing  (n  =  9)  or  reducing  (n  =  4)  BP.
In  our  study,  an  ARR  determination  was  performed  at  rest
nd  during  an  orthostatic  stimulation  test,  as  recommended
hen  our  study  was  implemented.  In  2006,  there  was  no
lear  consensus  on  the  diagnostic  usefulness  of  conﬁrmatory
ests  (sodium  loading  test,  ﬂudrocortisone  suppression  test,
aptopril  challenge  test)  [4].  Considering  the  further  pub-
ished  recommendations  [30], the  lack  of  conﬁrmatory  tests
hould  be  taken  into  account  when  interpreting  our  study.
The  population  in  which  the  ROC  analysis  is  applied  is
lso  of  major  importance.  To  our  knowledge,  ROC  curve
nalysis  has  been  used  mainly  in  case-control  studies.  Such
 selection  of  subjects  artiﬁcially  increases  the  number  of
PAs  in  the  tested  population  and  the  deﬁnition  of  con-
rols  is  also  somewhat  arbitrary.  Sensitivity  and  speciﬁcity
ould  be  artiﬁcially  increased.  Thus,  a  small  bias  in  select-
ng  the  control  population  may  result  in  great  variations  in
ut-off  values,  which  are  based  on  sensitivity  and  speci-
city.  Furthermore,  positive  and  negative  predictive  values
annot  be  calculated  accurately  in  case-control  studies.
o  avoid  such  sampling  bias,  we  implemented  prospective
egisters  in  17  secondary  or  tertiary  hypertension  cen-
res.  Adherence  of  centres  to  the  register  was  voluntary;
his  can  be  regarded  as  a  limitation  of  our  study.  On  the
ther  hand,  the  centres  were  scattered  all  over  France
nd  can  be  considered  as  representative.  To  avoid  selection
ias,  investigators  were  instructed  to  register  consecu-
ive  case  reports  from  October  2006  to  June  2007.  We
hecked  the  possible  centre  effect  by  analysis  of  variance
Anova).  The  main  characteristics  of  our  included  patients
ere  similar  to  those  usually  reported  in  the  literature
18].
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[Aldosterone-to-renin  ratio  and  aldosterone-producing  adeno
The  main  limitation  in  our  ‘real-life  multicentre  study’
is  that  biological  variables  were  determined  in  each  centre
and  thus  were  not  standardized.  However,  when  a  central
laboratory  is  used,  results  are  valid  only  if  performed  in  that
laboratory.  Our  approach  was  more  pragmatic  and  thus  the
results,  which  may  be  considered  as  less  accurate,  can  be
applied  to  different  centres.
AVS  is  the  most  accurate  means  of  differentiating
between  uni-  and  bilateral  forms  of  PA.  However,  it  remains
difﬁcult  and  should  be  undertaken  only  by  trained  physi-
cians.  AVS  can  lead  to  false-negative  results,  especially
for  right  APA  [31]. Thus,  AVS  that  was  performed  only
in  six  operated  patients  over  12  was  not  taken  into
account  when  analysing  our  results.  However,  the  per-
centage  of  PA  patients  systematically  submitted  to  AVS
ranged  from  19%  to  100%  in  referral  centres  for  endocrine
hypertension  worldwide  [32]. Even  in  specialized  cen-
tres,  success  rates  for  AVS  were  poor  [33]. However,  AVS
remains  recommended  before  surgery  [30]. In  our  study,
the  absence  of  AVS  should  not  have  interfered  with  our
results  as  only  patients  with  histologically  documented
adenoma  were  used  as  references  in  the  ROC  analy-
sis.  Usually,  surgery  efﬁciency  is  conﬁrmed  by  BP  and
kalaemia  determinations.  A  postsurgery  measure  of  plasma
aldosterone  was  not  performed  in  our  pragmatic  clinical
study.
One  criterion  for  deciding  the  cut-off  value  of  a  test
is  to  maximize  the  sum  of  sensitivity  and  speciﬁcity
values  (Younden  coefﬁcient).  According  to  this  strategy,
the  proposed  ARR  cut-off  value  is  32  ng/ng.  However,
a  single  determination  of  ARR  did  not  provide  sufﬁ-
cient  sensitivity  for  clinical  practice.  A  second  value  of
ARR  ≥  32  ng/ng  after  at  least  1-hour  standing  increased
the  sensitivity  to  100%,  together  with  a  satisfactory  speci-
ﬁcity  of  72%.  However,  CT-scans  are  not  sensitive  enough
to  reveal  all  the  unilateral  APAs.  Thus,  our  ARR  cut-
off  value  can  only  be  considered  for  screening  for  APAs
that  can  be  visualized  by  CT-scan.  What  to  do  if  an
ARR  is  >  32  ng/ng  without  any  CT-scan  adrenal  abnormal-
ity  remains  to  be  explored.  Our  proposed  ARR  cut-off
value  of  ≥  32  ng/ng  is  not  far  from  the  one  determined
in  the  PAPY  study  (27.3  ng/mU  corresponding  to  38  ng/ng)
[25].
Conclusion
In  conclusion,  our  proposed  pragmatic  approach,  based
on  an  ARR  cut-off  value  ≥  32  ng/ng  in  one  of  two
determinations,  with  a  minimal  active  renin  value
set  at  5  ng/L  (or  minimal  aldosterone  at  160  ng/L),
diagnosed  APA  with  very  good  sensitivity  and  satisfac-
tory  speciﬁcity.  Although  determined  in  a  prospective
multicentre  study,  this  cut-off  value  must  be  con-
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